Published in Bone Marrow Transplant on August 01, 2000
Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol (2004) 1.27
Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am J Hum Genet (2012) 1.11
Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J (2007) 1.09
Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med (2013) 0.94
Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther (2011) 0.88
Lysosomal Storage Diseases. Curr Treat Options Neurol (2001) 0.87
In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab (2008) 0.83
Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach. Ann Rheum Dis (2006) 0.80
Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation. Eur J Pediatr (2013) 0.79
Nervous system involvement in Farber disease. J Inherit Metab Dis (2015) 0.76
Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy. Neural Plast (2017) 0.75
Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex (2000) 3.69
Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A (1981) 2.83
Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. Nat Genet (1995) 2.62
MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol (1995) 2.42
A unified nomenclature for peroxisome biogenesis factors. J Cell Biol (1996) 2.25
Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol (1993) 2.07
Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol (1999) 2.06
Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology (2003) 1.92
Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol (1984) 1.83
Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology (1981) 1.81
Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology (2005) 1.77
Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A (1984) 1.75
Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol (2001) 1.71
Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol (1980) 1.71
Hyperornithinemia, hyperammonemia, and homocitrullinuria. A new disorder of amino acid metabolism associated with myoclonic seizures and mental retardation. Am J Dis Child (1969) 1.65
The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. EMBO J (1996) 1.62
The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis. N Engl J Med (1984) 1.56
Optic nerve hypoplasia: absence of posterior pituitary bright signal on magnetic resonance imaging correlates with diabetes insipidus. Am J Ophthalmol (1996) 1.53
Intracranial ganglioglioma: MR, CT, and clinical findings in 18 patients. AJR Am J Roentgenol (1990) 1.48
Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet (1986) 1.47
Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet (1998) 1.47
Complementation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. Hum Genet (1992) 1.46
ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat (2001) 1.45
Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. Nat Genet (1997) 1.44
Treatment of brain tumors in children is associated with abnormal MR spectroscopic ratios in brain tissue remote from the tumor site. AJNR Am J Neuroradiol (1998) 1.43
Duplex Doppler sonography of the carotid artery: false-positive results in an artery contralateral to an artery with marked stenosis. AJR Am J Roentgenol (1990) 1.40
Identification of three distinct peroxisomal protein import defects in patients with peroxisome biogenesis disorders. J Cell Sci (1995) 1.40
Cerebro-hepato-renal (Zellweger) syndrome and neonatal adrenoleukodystrophy: similarities in phenotype and accumulation of very long chain fatty acids. Johns Hopkins Med J (1982) 1.39
Clinical, neurodiagnostic, and MR findings in children with spinal and brain stem multiple sclerosis. AJNR Am J Neuroradiol (1995) 1.39
Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science (1984) 1.39
Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol (1998) 1.35
Frequent alterations of visual pigment genes in adrenoleukodystrophy. Am J Hum Genet (1988) 1.32
Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet (1996) 1.31
Metabolic control of peroxisome abundance. J Cell Sci (1999) 1.31
Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders. Am J Hum Genet (1998) 1.31
Loss of rubella antibody from immune globulin treated with kaolin. Appl Microbiol (1969) 1.29
Standardization of complementation grouping of peroxisome-deficient disorders and the second Zellweger patient with peroxisomal assembly factor-1 (PAF-1) defect. Am J Hum Genet (1993) 1.29
The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol (1992) 1.27
Adrenoleukodystrophy: studies of the phenotype, genetics and biochemistry. Johns Hopkins Med J (1980) 1.23
Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res (1984) 1.21
Linkage of adrenoleukodystrophy to a polymorphic DNA probe. Ann Neurol (1987) 1.20
A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A (1997) 1.20
Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol (2001) 1.19
Maternal drug use during pregnancy: are preterm and full-term infants affected differently? Dev Psychol (1998) 1.19
Apparent biochemical homozygosity in two obligatory heterozygotes for metachromatic leukodystrophy. J Pediatr (1976) 1.19
Intracranial aneurysms in infants and children. Pediatr Radiol (1998) 1.18
Effects of prenatal alcohol exposure at school age. II. Attention and behavior. Neurotoxicol Teratol (1991) 1.18
Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol (2000) 1.17
Solubilization and partial purification of steroid sulfatase from rat liver: characterization of estrone sulfatase. Arch Biochem Biophys (1976) 1.16
Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies. Science (1985) 1.15
Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol (2001) 1.15
Melanotic neuroectodermal tumor of infancy. MR findings and a review of the literature. Pediatr Radiol (1989) 1.15
Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim Biophys Acta (1975) 1.15
The three-dimensional structure of the seed storage protein phaseolin at 3 A resolution. EMBO J (1990) 1.14
Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem Res (1999) 1.11
Identification of a fatty acid delta6-desaturase deficiency in human skin fibroblasts. J Lipid Res (2001) 1.10
Neonatal neurobehavioral characteristics as correlates of maternal alcohol use during gestation. Alcohol Clin Exp Res (1985) 1.10
Neurocognitive functioning and magnetic resonance imaging in children with sickle cell disease. J Pediatr Psychol (2000) 1.09
MR of Leigh's disease (subacute necrotizing encephalomyelopathy). AJNR Am J Neuroradiol (1987) 1.08
Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet (1995) 1.08
Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. Am J Hum Genet (1999) 1.08
Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science (1972) 1.08
Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab (1999) 1.07
Identifying high-risk pregnant drinkers: biological and behavioral correlates of continuous heavy drinking during pregnancy. J Stud Alcohol (1987) 1.07
Hyperuricemia in Down's syndrome. J Clin Endocrinol Metab (1968) 1.07
A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol (1987) 1.06
MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol (1998) 1.06
Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochem Biophys Res Commun (1981) 1.06
High concentration of hexacosanoate in cultured skin fibroblast lipids from adrenoleukodystrophy patients. Biochem Biophys Res Commun (1978) 1.05
The effects of prenatal drug exposure, term status, and caregiving on arousal and arousal modulation in 8-week-old infants. Dev Psychobiol (2000) 1.05
Familial X-linked Addison disease as an expression of adrenoleukodystrophy (ALD): elevated C26 fatty acid in cultured skin fibroblasts. Neurology (1982) 1.05
Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry (1996) 1.05
Intracranial ganglioglioma: MR, CT, and clinical findings in 18 patients. AJNR Am J Neuroradiol (1990) 1.04
Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurology (2001) 1.03
Brain lipids, proteolipids, and free amino acids in maple syrup urine disease. J Neurochem (1966) 1.03
New approaches in peroxisomal disorders. Dev Neurosci (1987) 1.03
Development of myelin in inherited disorders of amino acid metabolism. Arch Neurol (1968) 1.02
Plasma amino acid concentrations and amino acid ratios in normal adults and adults heterozygous for phenylketonuria ingesting a hamburger and milk shake meal. Am J Clin Nutr (1991) 1.02
Peroxisome assembly mutations in humans: structural heterogeneity in Zellweger syndrome. J Cell Physiol (1992) 1.01
Solvent vapor abuse leukoencephalopathy. Comparison to adrenoleukodystrophy. J Neuropathol Exp Neurol (1994) 1.00
Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol (1982) 1.00
Peroxisomal straight-chain Acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis. J Biol Chem (2001) 1.00
Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol (2001) 0.99
Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis (1986) 0.99
Leptomeningeal metastasis: MR imaging. Radiology (1987) 0.99
X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol (2000) 0.99
Stimulation of acid ceramidase activity by saposin D. Arch Biochem Biophys (1994) 0.99
The peroxisome deficient PEX2 Zellweger mouse: pathologic and biochemical correlates of lipid dysfunction. J Mol Neurosci (2001) 0.99
Nonaccidental pediatric head injury: diffusion-weighted imaging findings. Neurosurgery (2001) 0.97
A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects. Eur J Pediatr (1985) 0.97
Moyamoya disease in the United States. Clin Neurol Neurosurg (1997) 0.97
Neuroimaging studies in Rett syndrome. Brain Dev (2001) 0.96
Modification of the schedule of myelination in the rat by early nutritional deprivation. Pediatrics (1966) 0.96
A fibroblast cell line defective in alkyl-dihydroxyacetone phosphate synthase: a novel defect in plasmalogen biosynthesis. Proc Natl Acad Sci U S A (1997) 0.95
Non-infantile neuronopathic Gaucher's disease: a clinicopathologic study. Neurology (1983) 0.95
Hemorrhage within pituitary adenomas: how often associated with pituitary apoplexy syndrome? AJR Am J Roentgenol (1989) 0.94
Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts. J Pediatr (1976) 0.94
The nosology of mental retardation: including the report of a survey of 1378 mentally retarded individuals at the Walter E. Fernald State School. Birth Defects Orig Artic Ser (1971) 0.94
Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol (1985) 0.94
Peroxisomal disorders. J Pediatr (1986) 0.94